letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12345678910111213...99100»
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (clinicaltrials.gov) -  Jan 31, 2025   
    P4,  N=96, Terminated, 
    N=565 --> 96 | Trial completion date: Jan 2029 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jan 2025; The study had to be terminated due to the new European legislation on drug studies. This legislation requires all studies aimed at evaluating treatments to be registered as such, even in the context of Standard of Care.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Trial completion date:  Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) -  Jan 31, 2025   
    P4,  N=65, Completed, 
    This legislation requires all studies aimed at evaluating treatments to be registered as such, even in the context of Standard of Care. Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Dec 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Jan 28, 2025   
    P2,  N=102, Recruiting, 
    Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026 Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Oct 2024 --> Oct 2027
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Characteristics of polycystic ovary syndrome rat models induced by letrozole, testosterone propionate and high-fat diets. (Pubmed Central) -  Jan 27, 2025   
    Letrozole is useful for studies on metabolic disturbances in PCOS, and LE+HFD treatment is suitable for investigations on PCOS metabolic abnormalities and the gut-PCOS link. Testosterone propionate injection is appropriate for studying reproductive abnormalities in PCOS, while TP+HFD treatment is the most comprehensive for studying PCOS reproductive abnormalities, metabolic disturbances and the gut-PCOS link.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial withdrawal:  Hormone Secretion in Transgender Males (clinicaltrials.gov) -  Jan 13, 2025   
    P4,  N=0, Withdrawn, 
    Suspended --> Recruiting N=40 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Investigating the self-healing potential of polycystic ovary syndrome in a mouse model: Implications for offspring health. (Pubmed Central) -  Jan 12, 2025   
    The synergistic effect of adropin and Tirze is mostly mediated via activating the cardiac Akt, which dampens the GSK3?/NF-?B/NLRP3 signaling pathway, with a sequel of alleviating oxidative damage, inflammatory response, ER stress, and related apoptosis, making them alluring desirable therapeutic targets in PCOS-associated cardiac complications. Female C57 BL/6J mice aged 4-5 weeks were administered letrozole (1
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Fertility journey of a patient with McCune-Albright syndrome associated with bilateral ovarian involvement. (Pubmed Central) -  Jan 12, 2025   
    Spontaneous ovulation was resumed in this patient using lanreotide which regulated IGF-1 levels after unsuccessful ovulation induction with letrozole...Two frozen embryo transfer cycles were completed and she achieved a pregnancy, which unfortunately ended in an incomplete miscarriage. Through IVF and near-normalization of IGF-1 using lanreotide, pregnancy was achieved in a patient with MAS who had achieved good ovarian stimulation despite a history of bilateral ovarian involvement and associated hyperfunctioning endocrinopathies.
  • ||||||||||  letrozole / Generic mfg., fulvestrant / Generic mfg.
    Journal:  Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. (Pubmed Central) -  Jan 12, 2025   
    P2
    Pharmacological inhibition of mitochondrial complex I suppressed the tumor-forming potential of persisters in mice and synergized with the anti-estrogen fulvestrant to induce regression of patient-derived xenografts. These findings indicate that mitochondrial metabolism is essential in endocrine-tolerant persister ER+ breast cancer cells and warrant the development of treatment strategies to leverage this vulnerability for treating breast cancer.
  • ||||||||||  Journal, Adverse events, Real-world evidence:  Real world pharmacovigilance assessment of drug related macular degeneration risks. (Pubmed Central) -  Jan 12, 2025   
    Lifitegrast, nicotine, and travoprost were associated with the shortest onset times for ocular adverse events...The incidence of drug-related macular degeneration has steadily increased in recent years. This study offers valuable pharmacovigilance insights, highlighting drugs and demographic factors linked to macular degeneration.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Review, Journal:  Concurrent use of Radiotherapy and Ribociclib: Preliminary Results and Review of the Literature. (Pubmed Central) -  Jan 6, 2025   
    This study offers valuable pharmacovigilance insights, highlighting drugs and demographic factors linked to macular degeneration. Despite the need for further investigation, our results suggest safety consistent with pivotal trials, advocating for a prospective cooperative data collection initiative to explore this combined strategy further, potentially revolutionizing metastatic breast cancer management.
  • ||||||||||  Bone Metastases In Late Recurrence Of Adult Granulosa Cell Tumor Of The Ovary (Poster area) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_969;    
    She received six cycles of carboplatin-paclitaxel followed by four cycles of cisplatin-etoposide...Postoperatively, chemotherapy was planned but halted due to cardiac failure, and letrozole therapy was started...In this case, aggressive surgery, chemotherapy, and palliative care provided short-term relief, but the atypical recurrence pattern highlights the challenges in managing AGCT recurrences. Close monitoring with imaging and inhibin levels may help guide follow-up, but treatment strategies for distant metastases, particularly bone involvement, require further research.
  • ||||||||||  letrozole / Generic mfg.
    Wire Localisation In Recurrent Ovarian Cancer Surgery: Case Series (Poster area) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_731;    
    A 33-year-old female with Stage 3B low-grade serous ovarian carcinoma (LGSOC) underwent primary CRS and HIPEC in 2021, followed by adjuvant chemotherapy and maintenance letrozole...This technique, often reserved for breast and thoracic surgeries, proves valuable in pelvic surgeries involving anatomically challenging recurrences. Wire localisation facilitated complete resection of non-palpable lesions, supporting optimal patient outcomes.
  • ||||||||||  letrozole / Generic mfg.
    Letrozole, An Old Drug  (Poster area) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_192;    
    Table- Comparison of recurrence between letrozole and control groups. Conclusion This study highlights Letrozole's potential in managing ER-positive HGSOC, showing promise in prolonging recurrence-free intervals and improving outcomes, warranting further research to fully understand its role and safety.
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  The role of Letrozole in IVF treatment: new remedy or old mirage? (Pubmed Central) -  Dec 29, 2024   
    In this article, evidence supporting the role of adjuvant letrozole in poor responders, as a moderator of OHSS symptoms, and an agent for improving the luteal phase after ovarian stimulation is reviewed. The use of letrozole for endometrial preparation in the frozen-thawed embryo transfer cycle is also considered.
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  Ovarian stimulation 2.0. (Pubmed Central) -  Dec 29, 2024   
    In the past decade, we have seen a flurry of various new protocols used for OS in ART. In light of the important differences that characterize these new approaches for OS, we felt is was timely to review the relative merit of each and every new protocol.
  • ||||||||||  letrozole / Generic mfg., irinotecan / Generic mfg.
    Journal:  Data-driven discovery of cell-type-directed network-correcting combination therapy for Alzheimer's disease. (Pubmed Central) -  Dec 23, 2024   
    Single-nuclei transcriptomic analysis confirmed that the therapy reversed disease-associated gene networks in a cell-type-specific manner. These results highlight the promise of cell-type-directed combination therapies in addressing multifactorial diseases like AD and lay the groundwork for precision medicine tailored to patient-specific transcriptomic and clinical profiles.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal, FDG PET, Metastases:  The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting. (Pubmed Central) -  Dec 19, 2024   
    Most patients received fulvestrant (31 patients, 79%), whereas eight patients (21%) were treated with letrozole...FDG-PET-CT performed before cyclin-dependent kinase 4/6 inhibitor commencement is a valuable prognostic tool in hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. Patients with SUVmax less than 8.4 experienced extended progression-free survival compared to those with higher SUVmax.
  • ||||||||||  Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (Pubmed Central) -  Dec 18, 2024   
    Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
  • ||||||||||  Tukysa (tucatinib) / Pfizer, Nerlynx (neratinib) / Puma
    Journal:  Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs. (Pubmed Central) -  Dec 18, 2024   
    In contrast, anastrozole and letrozole show lower binding affinities for HER2 and EGFR due to their simpler structures but are potent aromatase inhibitors, making them effective in treating estrogen receptor-positive (ER-positive) breast cancers. In conclusion, DFT and molecular docking studies affirm the suitability of lapatinib, tucatinib, and neratinib for HER2-positive cancers, while anastrozole and letrozole are effective in ER-positive cancers, emphasizing the role of molecular structure and binding affinity in optimizing cancer treatment strategies.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Enrollment open:  Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer (clinicaltrials.gov) -  Dec 17, 2024   
    P2,  N=71, Recruiting, 
    In conclusion, DFT and molecular docking studies affirm the suitability of lapatinib, tucatinib, and neratinib for HER2-positive cancers, while anastrozole and letrozole are effective in ER-positive cancers, emphasizing the role of molecular structure and binding affinity in optimizing cancer treatment strategies. Not yet recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal, IO biomarker:  Recurrent Implantation Failure and Innovative Therapeutic Options: A Systematic Review. (Pubmed Central) -  Dec 14, 2024   
    According to the studies examined, various methods were used to regenerate and improve the thickness of the endometrium, including the use of growth hormone, letrozole, medroxyprogesterone acetate, granulocyte colony-stimulating factor, platelet-rich plasma (PRP), lymphocytes immunotherapy, and endometrial scratch...Further research is necessary to confirm their clinical utility. However, more research is also needed to establish the safety and efficacy of these cell-based therapies.
  • ||||||||||  zoledronic acid / Generic mfg.
    Journal:  Efficacy of a single 5 (Pubmed Central) -  Dec 10, 2024   
    Ascorbic acid mitigated the behavioural difficulties of PCOS possibly by switching-off JAK2/STAT5 and JAK2/ERK1/2 pathways in hippocampus along with its neurotransmission-improving, hormonal-normalizing, anti-hyperglycemic and anti-oxidative effects. A single infusion of 5